“These findings highlight the need for early interventions to mitigate the significant morbidity and mortality burden associated with an AKI event in patients with and without CKD,” Schulman said. “While the best post-AKI clinical management regimen is yet to be determined, these results underscore the immediate need for close posthospitalization monitoring of individuals with AKI.”
Manish Sood, M.D., of the Ottawa Hospital Research Institute in Canada, and colleagues found that a new risk equation, referred to as the Kidney Disease Risk Equation (KDRE), can accurately predict the risk for developing kidney disease.
The authors used data from more than 1.1 million individuals in Ontario to develop a new risk equation that uses readily available information to identify people at high risk for developing early kidney disease. The risk equation includes age, sex, history of diabetes and/or hypertension, and laboratory test results (hemoglobin, kidney function) and can be calculated with or without a urine albuminuria test. The researchers found that the KDRE was accurate in predicting the five-year risk for developing new chronic kidney disease (CKD) defined by an estimated glomerular filtration rate less than 60 mL/min.
“The KDRE has a number of potential uses, including: (i) determining an individual patient’s CKD risk at the bedside; (ii) incorporation into existing health systems (online calculators) to identify at-risk individuals; (iii) to determine at a population level emerging CKD risk and health care planning; and (iv) as a research tool to identify high-risk patients and trial enrollment,” Sood explained.
ASN: Steroids Best Placebo in High-Risk IgA Nephropathy
TUESDAY, Nov. 16, 2021 (HealthDay News) — Steroids reduce the risk for major adverse kidney outcomes in people with high-risk immunoglobulin A nephropathy, but full-dose methylprednisolone increased the risk for serious adverse events, according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held virtually from Nov. 4 to 7.
ASN: Ellipsys Percutaneous Fistula Durable for Hemodialysis Access
TUESDAY, Nov. 16, 2021 (HealthDay News) — A percutaneous arteriovenous fistula created by an interventionalist in the office-based lab provides durable access for hemodialysis through five years, according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held virtually from Nov. 4 to 7.
ASN: PPI Use May Up Risk for AKI After Cardiac Surgery
MONDAY, Nov. 15, 2021 (HealthDay News) — Preoperative proton pump inhibitor use is associated with incident acute kidney injury in patients undergoing cardiac surgery, according to a study presented at Kidney Week, the annual meeting of the American Society of Nephrology, held virtually from Nov. 4 to 7.
ASN: Model Predicts Benefit of SGLT2 Inhibitors for Adults With T1DM